Search Results

You are looking at 1 - 10 of 91 items for :

  • Refine by Access: All Content x
Clear All

 1. Summary of results Code System Frequency DBT/MDMA-AT overlap 83 Concerns for MDMA-AT for BPD (+) 15 Modification for BPD Dx 5 Regression 4 Limitations of DBT/MDMA-AT treatment alone 0 Limitations of traditional treatment modalities (not/MDMA

Open access

/Self-Validation 4 Emotional Dysregulation 6 Understanding Emotions 4 Emotional Self-Validation 7 Wise Mind 2 Support Network 5 Stigma-Lack of Access 10 De-Stigmatization 2 Lack of Access 5 Phase 2-MDMA-AT 0 MDMA Therapy Orientation 6 Therapist Role 2 Suicidality 5

Open access

Multidisciplinary Association for Psychedelic Studies (MAPS) and MAPS Public Benefit Corporation (MAPS PBC) have been at the forefront of addressing PTSD by working to make 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy into a legal prescription

Open access

Introduction ±3,4-Methylenedioxymethamphetamine (MDMA), the active ingredient of the street drug Ecstasy, was studied initially as an adjunct psychotherapeutic tool, prior to its nationwide prohibition. It was first termed

Open access

and validate an analytical method for the determination of methamphetamine, amphetamine, morphine, monoacetylmorphine, ketamine, norketamine, 3,4-methylenedioxymethamphetamine (MDMA), and 3,4-methylenedioxyamphetamine (MDA) in human hair based on

Open access

people with various drug dependence, all which are described later. To date, 3,4,-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy research has focused primarily on post-traumatic stress disorder (PTSD). However, MDMA has never been explored as

Open access

,4,-methylenedioxymethamphetamine (MDMA)-assisted therapist training program and have served as therapists with the MAPS-sponsored trials of MDMA-assisted treatment of PTSD at NYUSoM. Currently, both authors are also part of a team conducting a qualitative interview study of

Open access

,4-methylenedioxymethamphetamine (MDMA) being used for a variety of indications ( Costandi, 2014; Passie, 2018 ). Current clinical research is exploring the safety and efficacy of psychedelics for mental health disorders, such as posttraumatic stress disorder (PTSD), mood

Open access

for psychedelic-assisted treatments currently. For example, a recent Phase III trial of MDMA-assisted treatment for post-traumatic stress disorder represents years of herculean work performed in multiple nations and reveals a promising effect size of

Open access

should consider that MDMA-assisted psychotherapy, the first P-AT likely to be federally approved, has been used to treat patients specifically with PTSD ( Mitchell et al., 2021 ). Because PTSD is a common outcome of sexual abuse ( Scott et al., 2017 ) and

Open access